[1] Francis F, Hennig S, Korn B, et al.A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets[J]. Nat Genet, 1995, 11(2): 130-136.
[2] Haffner D, Emma F, Eastwood DM, et al.Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia[J]. Nat Rev Nephrol, 2019, 15(7): 435-455.
[3] Shimada T, Hasegawa H, Yamazaki Y, et al.FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis[J]. J Bone Miner Res, 2004, 19(3): 429-435.
[4] Gaucher C, Walrant-Debray O, Nguyen TM, et al.PHEX analysis in 118 pedigrees reveals new genetic clues in hypophosphatemic rickets[J]. Hum Genet, 2009, 125(4): 401-411.
[5] 中华医学会内分泌学分会,中华医学会骨质疏松和骨矿盐疾病分会. 中国低血磷性佝偻病/骨软化症诊疗指南[J]. 中华骨质疏松和骨矿盐疾病杂志,2022,15(2): 107-125.
[6] Lyseng-Williamson KA.Burosumab in X-linked hypophosphatemia: a profile of its use in the USA[J]. Drugs Ther Perspect, 2018, 34(11): 497-506.
[7] Insogna KL, Briot K, Imel EA, et al.A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis[J]. J Bone Miner Res, 2018, 33(8): 1383-1393. |
